ARS Pharmaceuticals Investors Can Lead SPRY Securities Fraud Lawsuit
Rosen Law Firm reminds purchasers of ARS Pharmaceuticals, Inc. securities between March and June 2026 of an October 5 deadline to serve as lead plaintiff in a securities fraud lawsuit.
Rosen Law Firm has notified purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities that they may have the opportunity to serve as lead plaintiff in a securities fraud class action lawsuit against the company.
The deadline for investors to seek appointment as lead plaintiff is October 5, 2026. The lawsuit concerns alleged securities fraud related to the company's stock trading between March 9, 2026, and June 24, 2026.
Rosen Law Firm, which focuses on investor rights litigation, is encouraging ARS Pharmaceuticals investors who incurred losses during the specified period to contact the firm. Investors may be able to recover their losses and potentially receive compensation for certain out-of-pocket expenses.
Serving as lead plaintiff allows an investor to have a significant voice in the litigation and potentially recover additional funds for damages.